Your browser is no longer supported. Please, upgrade your browser.
Settings
BDTX [NASD]
Black Diamond Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own2.10% Shs Outstand35.93M Perf Week-12.25%
Market Cap998.45M Forward P/E- EPS next Y-2.52 Insider Trans-50.01% Shs Float34.29M Perf Month-17.01%
Income-54.50M PEG- EPS next Q-0.62 Inst Own86.20% Short Float10.11% Perf Quarter-11.40%
Sales- P/S- EPS this Y-294.80% Inst Trans-7.44% Short Ratio10.05 Perf Half Y-8.06%
Book/sh9.11 P/B2.87 EPS next Y-24.10% ROA-17.90% Target Price- Perf Year-
Cash/sh8.71 P/C3.00 EPS next 5Y- ROE-22.30% 52W Range17.63 - 46.25 Perf YTD-18.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.55% Beta-
Dividend %- Quick Ratio29.70 Sales past 5Y- Gross Margin- 52W Low48.10% ATR2.10
Employees32 Current Ratio29.70 Sales Q/Q- Oper. Margin- RSI (14)29.49 Volatility7.33% 7.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-75.60% Profit Margin- Rel Volume1.30 Prev Close26.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume344.88K Price26.11
Recom1.60 SMA20-17.47% SMA50-20.26% SMA200-21.69% Volume441,326 Change-3.12%
Jan-07-21Initiated Wedbush Outperform $45
Nov-24-20Initiated Berenberg Buy $58
May-04-20Initiated H.C. Wainwright Buy $53
Feb-24-20Initiated JP Morgan Overweight $42
Feb-24-20Initiated Jefferies Buy
Feb-24-20Initiated Cowen Outperform
Feb-24-20Initiated Canaccord Genuity Buy $50
Jan-20-21 07:45AM  
Jan-05-21 07:45AM  
Dec-14-20 12:51PM  
Dec-05-20 01:55AM  
Nov-24-20 07:45AM  
Nov-20-20 07:45AM  
Nov-11-20 07:45AM  
Nov-10-20 07:45AM  
Oct-26-20 07:45AM  
Oct-12-20 07:45AM  
Oct-03-20 08:00AM  
Sep-29-20 07:45AM  
Sep-10-20 07:45AM  
Sep-08-20 04:05PM  
Aug-11-20 07:45AM  
Aug-10-20 08:42AM  
Aug-05-20 07:45AM  
Aug-04-20 07:45AM  
Jul-30-20 09:58AM  
Jul-28-20 07:45AM  
Jun-16-20 07:45AM  
May-27-20 07:45AM  
May-13-20 05:15PM  
May-12-20 07:45AM  
May-06-20 07:45AM  
May-05-20 11:46AM  
Feb-24-20 09:37AM  
Jan-30-20 04:29PM  
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hatzis-Schoch BrentSee RemarksJan 12Option Exercise8.1611,57894,50019,978Jan 14 08:57 PM
Hatzis-Schoch BrentSee RemarksJan 12Sale34.0311,578394,0418,400Jan 14 08:57 PM
Leggett ThomasChief Financial OfficerJan 08Option Exercise10.863,00032,5803,000Jan 11 05:59 PM
Leggett ThomasChief Financial OfficerJan 08Sale33.943,000101,8200Jan 11 05:59 PM
Epstein David M.See RemarksJan 04Option Exercise6.423,00019,260708,423Jan 06 06:21 PM
Roberts Christopher D.Chief Scientific OfficerJan 04Option Exercise10.862,50027,1505,700Jan 06 06:27 PM
Epstein David M.See RemarksJan 04Sale31.1312,000373,505696,423Jan 06 06:21 PM
Roberts Christopher D.Chief Scientific OfficerJan 04Sale31.412,50078,5253,200Jan 06 06:27 PM
Hatzis-Schoch BrentSee RemarksDec 28Option Exercise3.205,40017,2808,400Dec 29 04:46 PM
Epstein David M.See RemarksDec 15Option Exercise6.422,50016,050705,423Dec 16 07:39 PM
Roberts Christopher D.Chief Scientific OfficerDec 15Option Exercise10.863,20034,7523,200Dec 16 07:42 PM
Hatzis-Schoch BrentSee RemarksDec 14Option Exercise3.204,07813,0507,078Dec 16 07:41 PM
Hatzis-Schoch BrentSee RemarksDec 14Sale34.954,078142,5223,000Dec 16 07:41 PM
Leggett ThomasChief Financial OfficerDec 08Option Exercise10.863,00032,5803,000Dec 10 04:16 PM
Leggett ThomasChief Financial OfficerDec 08Sale33.783,000101,3270Dec 10 04:16 PM
Roberts Christopher D.Chief Scientific OfficerDec 03Option Exercise10.862,50027,1502,500Dec 04 04:34 PM
Roberts Christopher D.Chief Scientific OfficerDec 03Sale32.422,50081,0550Dec 04 04:34 PM
Epstein David M.See RemarksDec 01Option Exercise6.423,00019,260714,923Dec 03 04:17 PM
Epstein David M.See RemarksDec 01Sale32.7112,000392,574702,923Dec 03 04:17 PM
Versant Venture Capital VI, L.10% OwnerNov 30Sale33.1510,393344,513874,099Dec 01 07:13 PM
Bolzon Bradley J PhDDirectorNov 30Sale33.1510,393344,513874,099Dec 01 07:13 PM
Bolzon Bradley J PhDDirectorNov 19Sale33.01130,0174,291,861968,954Nov 23 04:39 PM
Versant Venture Capital VI, L.10% OwnerNov 19Sale33.01114,8543,791,3314,818,600Nov 23 04:41 PM
Versant Venture Capital VI, L.10% OwnerNov 19Sale33.0115,163500,531968,954Nov 23 04:41 PM
Versant Venture Capital VI, L.10% OwnerNov 18Sale33.09632,085984,117Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 18Sale33.0947315,6534,933,454Nov 19 09:19 PM
Bolzon Bradley J PhDDirectorNov 18Sale33.0953617,738984,117Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 17Sale33.0548916,161984,180Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 17Sale33.053,705122,4504,933,927Nov 19 09:19 PM
Bolzon Bradley J PhDDirectorNov 17Sale33.054,194138,611984,180Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 16Sale33.0123759984,669Nov 17 07:33 PM
Versant Venture Capital VI, L.10% OwnerNov 16Sale33.011775,8434,937,632Nov 17 07:33 PM
Bolzon Bradley J PhDDirectorNov 16Sale33.012006,603984,669Nov 17 07:28 PM
Versant Venture Capital VI, L.10% OwnerNov 13Sale33.7752517,731984,692Nov 17 07:33 PM
Versant Venture Capital VI, L.10% OwnerNov 13Sale33.773,975134,2534,937,809Nov 17 07:33 PM
Bolzon Bradley J PhDDirectorNov 13Sale33.774,500151,984984,692Nov 17 07:28 PM
Hatzis-Schoch BrentSee RemarksNov 12Option Exercise3.204,07813,0507,078Nov 13 04:25 PM
Versant Venture Capital VI, L.10% OwnerNov 12Sale34.151,81962,116985,217Nov 13 07:47 PM
Versant Venture Capital VI, L.10% OwnerNov 12Sale34.1513,779470,5264,941,784Nov 13 07:47 PM
Bolzon Bradley J PhDDirectorNov 12Sale34.1515,598532,642985,217Nov 13 07:46 PM
Hatzis-Schoch BrentSee RemarksNov 12Sale33.994,078138,6073,000Nov 13 04:25 PM
Roberts Christopher D.Chief Scientific OfficerNov 11Option Exercise10.865,00054,3005,000Nov 13 04:26 PM
Versant Venture Capital VI, L.10% OwnerNov 11Sale34.731,47151,091987,036Nov 12 05:41 PM
Versant Venture Capital VI, L.10% OwnerNov 11Sale34.7311,146387,1275,646,377Nov 12 05:41 PM
Bolzon Bradley J PhDDirectorNov 11Sale34.7312,617438,217987,036Nov 12 05:38 PM
Roberts Christopher D.Chief Scientific OfficerNov 11Sale34.905,000174,5000Nov 13 04:26 PM
Versant Venture Capital VI, L.10% OwnerNov 10Sale33.833,145106,381988,507Nov 12 05:41 PM
Versant Venture Capital VI, L.10% OwnerNov 10Sale33.8323,821805,7555,657,523Nov 12 05:41 PM
Bolzon Bradley J PhDDirectorNov 10Sale33.8326,966912,136988,507Nov 12 05:38 PM
Leggett ThomasChief Financial OfficerNov 09Option Exercise10.863,00032,5803,000Nov 12 05:00 PM
Bolzon Bradley J PhDDirectorNov 09Sale33.066,300208,250991,652Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 09Sale33.0673524,296991,652Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 09Sale33.065,565183,9545,681,344Nov 10 07:24 PM
Leggett ThomasChief Financial OfficerNov 09Sale32.963,00098,8920Nov 12 05:00 PM
Bolzon Bradley J PhDDirectorNov 06Sale33.133,100102,698992,387Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 06Sale33.1336211,993992,387Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 06Sale33.132,73890,7065,686,909Nov 10 07:24 PM
Bolzon Bradley J PhDDirectorNov 05Sale33.158,848293,287992,749Nov 06 04:49 PM
Versant Venture Capital VI, L.10% OwnerNov 05Sale33.151,03234,208992,749Nov 06 04:44 PM
Versant Venture Capital VI, L.10% OwnerNov 05Sale33.157,816259,0795,689,647Nov 06 04:44 PM
Bolzon Bradley J PhDDirectorNov 04Sale33.142,50082,839993,781Nov 06 04:49 PM
Versant Venture Capital VI, L.10% OwnerNov 04Sale33.142929,676993,781Nov 06 04:44 PM
Versant Venture Capital VI, L.10% OwnerNov 04Sale33.142,20873,1645,697,463Nov 06 04:44 PM
Roberts Christopher D.Chief Scientific OfficerNov 03Option Exercise10.862,50027,1502,500Nov 04 08:37 PM
Roberts Christopher D.Chief Scientific OfficerNov 03Sale31.952,50079,8730Nov 04 08:37 PM
Epstein David M.See RemarksNov 02Option Exercise6.423,00019,260723,923Nov 03 07:56 PM
Epstein David M.See RemarksNov 02Sale31.1412,000373,656711,923Nov 03 07:56 PM
Versant Venture Capital VI, L.10% OwnerOct 27Sale33.03933,072994,073Oct 28 05:58 PM
Versant Venture Capital VI, L.10% OwnerOct 27Sale33.0370723,3545,699,671Oct 28 05:58 PM
Bolzon Bradley J PhDDirectorOct 27Sale33.0380026,426994,073Oct 28 05:51 PM
Versant Venture Capital VI, L.10% OwnerOct 26Sale33.3094531,473994,166Oct 28 05:58 PM
Versant Venture Capital VI, L.10% OwnerOct 26Sale33.307,158238,3945,700,378Oct 28 05:58 PM
Bolzon Bradley J PhDDirectorOct 26Sale33.308,103269,867994,166Oct 28 05:51 PM
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.4349416,515995,111Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.433,739124,9985,707,536Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 19Sale33.434,233141,513995,111Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.571,01634,110995,605Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.577,697258,4105,711,275Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 16Sale33.578,713292,520995,605Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.0332710,802996,621Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.032,47381,6945,718,972Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 15Sale33.032,80092,496996,621Oct 20 08:03 PM
Bolzon Bradley J PhDDirectorOct 14Sale33.095,501182,031996,948Oct 15 07:26 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.0964221,244996,948Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.094,859160,7875,721,445Oct 15 07:22 PM
Bolzon Bradley J PhDDirectorOct 13Sale33.3911,739391,984997,590Oct 15 07:26 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.391,36945,713997,590Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.3910,370346,2715,726,304Oct 15 07:22 PM
Hatzis-Schoch BrentSee RemarksOct 12Option Exercise3.204,07813,0507,078Oct 14 04:32 PM
Hatzis-Schoch BrentSee RemarksOct 12Sale32.704,078133,3313,000Oct 14 04:32 PM
Bolzon Bradley J PhDDirectorOct 12Sale33.1140013,243998,959Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.11471,556998,959Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.1135311,6875,736,674Oct 13 07:41 PM
Bolzon Bradley J PhDDirectorOct 09Sale33.673,800127,933999,006Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.6744314,914999,006Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.673,357113,0185,737,027Oct 13 07:41 PM
Leggett ThomasChief Financial OfficerOct 08Option Exercise10.863,00032,5803,000Oct 09 04:12 PM
Bolzon Bradley J PhDDirectorOct 08Sale33.4718,425616,748999,449Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.472,14971,934999,449Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.4716,276544,8145,740,384Oct 13 07:41 PM
ALGS Aligos Therapeutics, Inc. daily Stock Chart
ALGS [NASD]
Aligos Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own21.90% Shs Outstand41.15M Perf Week2.49%
Market Cap1.41B Forward P/E- EPS next Y-3.13 Insider Trans0.00% Shs Float26.66M Perf Month33.23%
Income- PEG- EPS next Q-0.83 Inst Own39.70% Short Float7.35% Perf Quarter159.09%
Sales- P/S- EPS this Y-275.10% Inst Trans- Short Ratio9.96 Perf Half Y-
Book/sh- P/B- EPS next Y34.40% ROA- Target Price34.50 Perf Year-
Cash/sh1.70 P/C20.10 EPS next 5Y- ROE- 52W Range12.82 - 37.51 Perf YTD23.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.82% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low166.77% ATR3.53
Employees73 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)65.30 Volatility14.08% 11.83%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.24 Prev Close34.94
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume196.61K Price34.20
Recom1.70 SMA2013.91% SMA5044.19% SMA20057.75% Volume47,941 Change-2.12%
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Nov-10-20Initiated Jefferies Buy $26
Nov-10-20Initiated Cantor Fitzgerald Overweight $28
Jan-16-21 01:06AM  
Jan-07-21 08:00AM  
Dec-17-20 08:00AM  
Dec-07-20 08:00AM  
Nov-18-20 10:48AM  
Nov-16-20 08:00AM  
Nov-13-20 08:00AM  
Nov-12-20 08:00AM  
Oct-30-20 08:00AM  
Oct-23-20 06:00PM  
Oct-16-20 06:05PM  
05:22PM  
02:13PM  
Oct-15-20 10:19PM  
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR- agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California.
AKRO Akero Therapeutics, Inc. daily Stock Chart
AKRO [NASD]
Akero Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.16 Insider Own1.60% Shs Outstand34.00M Perf Week5.58%
Market Cap1.02B Forward P/E- EPS next Y-2.68 Insider Trans-4.54% Shs Float29.35M Perf Month17.26%
Income-65.10M PEG- EPS next Q-0.59 Inst Own93.80% Short Float8.62% Perf Quarter12.20%
Sales- P/S- EPS this Y4.50% Inst Trans-0.05% Short Ratio10.13 Perf Half Y-19.06%
Book/sh8.42 P/B3.55 EPS next Y-21.30% ROA-38.40% Target Price- Perf Year28.23%
Cash/sh8.52 P/C3.51 EPS next 5Y- ROE-40.90% 52W Range10.78 - 41.16 Perf YTD15.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.38% Beta-
Dividend %- Quick Ratio24.80 Sales past 5Y- Gross Margin- 52W Low177.27% ATR1.56
Employees13 Current Ratio24.80 Sales Q/Q- Oper. Margin- RSI (14)62.61 Volatility4.05% 6.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.40% Profit Margin- Rel Volume0.59 Prev Close30.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume249.74K Price29.89
Recom1.70 SMA2011.18% SMA507.58% SMA2004.34% Volume147,253 Change-0.96%
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-01-20Reiterated H.C. Wainwright Buy $33 → $45
Mar-02-20Initiated H.C. Wainwright Buy $33
Feb-10-20Initiated Canaccord Genuity Buy $36
Jul-15-19Initiated ROTH Capital Buy $34
Jul-15-19Initiated JP Morgan Overweight $28
Jul-15-19Initiated Jefferies Buy $28
Jul-15-19Initiated Evercore ISI Outperform $35
Jan-04-21 04:05PM  
Dec-12-20 10:07PM  
Nov-24-20 04:05PM  
Nov-13-20 08:00AM  
Nov-12-20 04:05PM  
Oct-21-20 04:05PM  
Oct-19-20 10:13AM  
Oct-16-20 07:30AM  
Oct-02-20 07:30AM  
Sep-30-20 08:00AM  
Sep-28-20 04:05PM  
Sep-24-20 07:30AM  
Sep-16-20 04:25PM  
Sep-13-20 08:48AM  
Sep-09-20 04:05PM  
Aug-12-20 04:05PM  
Jul-23-20 11:02AM  
Jul-21-20 11:00AM  
Jul-10-20 04:05PM  
Jul-07-20 08:15PM  
Jul-06-20 07:00AM  
Jul-02-20 08:21AM  
Jul-01-20 09:03AM  
08:12AM  
Jun-30-20 04:05PM  
Jun-29-20 04:05PM  
Jun-27-20 09:28PM  
Jun-17-20 08:00AM  
Jun-10-20 12:00PM  
11:30AM  
10:30AM  
08:00AM  
Jun-04-20 07:08AM  
May-27-20 09:24AM  
May-26-20 04:05PM  
May-22-20 11:30AM  
May-13-20 04:05PM  
May-08-20 12:00PM  
Apr-06-20 12:00PM  
08:58AM  
Mar-31-20 08:26AM  
06:00AM  
Mar-30-20 04:05PM  
Mar-16-20 11:19AM  
07:31AM  
Feb-14-20 11:55AM  
Jan-27-20 06:05AM  
Jan-13-20 08:00AM  
Jan-08-20 04:05PM  
Dec-19-19 05:51PM  
Dec-16-19 04:05PM  
Dec-14-19 07:22PM  
Nov-13-19 04:01PM  
Nov-12-19 07:00AM  
Nov-04-19 08:00AM  
Oct-31-19 02:07PM  
Sep-19-19 06:54AM  
Sep-04-19 07:00AM  
Aug-12-19 07:00AM  
Jul-09-19 10:07AM  
Jul-03-19 07:31AM  
Jul-02-19 04:05PM  
Jun-24-19 04:05PM  
Jun-20-19 11:44AM  
Jun-19-19 09:20PM  
Jun-18-19 12:10PM  
Jun-17-19 10:07AM  
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young JonathanChief Operating OfficerJan 08Sale28.1210,000281,200179,285Jan 11 07:54 PM
Cheng AndrewPresident & CEOJan 07Option Exercise0.6220,00012,300362,989Jan 11 07:57 PM
Young JonathanChief Operating OfficerJan 07Option Exercise0.627,5004,613189,285Jan 11 07:54 PM
Young JonathanChief Operating OfficerJan 04Sale25.293,06077,399181,785Jan 06 06:48 PM
Cheng AndrewPresident & CEODec 28Option Exercise0.627,4804,638342,989Dec 29 04:53 PM
Cheng AndrewPresident & CEODec 21Option Exercise0.6210,5006,510335,509Dec 23 04:19 PM
Bitterman KevinDirectorOct 09Sale28.9313,000376,09011,780Oct 14 04:54 PM
Apple Tree Partners IV, L.P.10% OwnerJul 10Buy36.00415,00014,940,0005,830,203Jul 14 04:46 PM
Harrison Seth LoringDirectorJul 10Buy36.00415,00014,940,0005,830,203Jul 14 04:45 PM
venBio Global Strategic Fund I10% OwnerJul 06Sale33.834,603155,7213,033,552Jul 06 07:00 PM
venBio Global Strategic Fund I10% OwnerJul 02Sale33.633,800127,8053,038,155Jul 06 07:00 PM
venBio Global Strategic Fund I10% OwnerJul 01Sale34.45108,0643,723,0103,041,955Jul 06 07:00 PM
PASG Passage Bio, Inc. daily Stock Chart
PASG [NASD]
Passage Bio, Inc.
Index- P/E- EPS (ttm)- Insider Own19.38% Shs Outstand45.50M Perf Week-18.09%
Market Cap1.10B Forward P/E- EPS next Y-3.12 Insider Trans0.00% Shs Float36.71M Perf Month-13.13%
Income- PEG- EPS next Q-0.72 Inst Own79.30% Short Float5.16% Perf Quarter35.91%
Sales- P/S- EPS this Y-257.30% Inst Trans0.40% Short Ratio8.08 Perf Half Y16.43%
Book/sh7.45 P/B3.06 EPS next Y-10.60% ROA- Target Price29.13 Perf Year-
Cash/sh6.98 P/C3.27 EPS next 5Y- ROE- 52W Range8.09 - 38.23 Perf YTD-10.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.31% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low182.08% ATR2.32
Employees20 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)39.59 Volatility10.57% 8.22%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume2.73 Prev Close27.31
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume234.58K Price22.82
Recom2.40 SMA20-16.12% SMA50-3.94% SMA20011.63% Volume619,912 Change-16.44%
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Jun-25-20Downgrade Goldman Buy → Neutral $28
Mar-25-20Initiated Chardan Capital Markets Buy $30
Mar-24-20Initiated JP Morgan Overweight $25
Mar-24-20Initiated Goldman Buy $27
Mar-24-20Initiated Cowen Outperform
Jan-21-21 07:48PM  
Jan-19-21 04:06PM  
07:00AM  
Jan-13-21 10:25AM  
Jan-11-21 07:00AM  
Jan-04-21 04:01PM  
07:00AM  
Dec-16-20 08:00AM  
Dec-15-20 11:10PM  
Dec-11-20 08:11AM  
Dec-10-20 04:01PM  
Dec-07-20 07:00AM  
Nov-24-20 03:55AM  
Nov-23-20 04:01PM  
Nov-11-20 04:30PM  
07:00AM  
Nov-10-20 07:00AM  
Nov-09-20 07:00AM  
Nov-04-20 07:00AM  
Oct-28-20 07:00AM  
Oct-26-20 07:00AM  
Oct-14-20 08:30AM  
Oct-13-20 04:30PM  
Oct-06-20 07:00AM  
Sep-25-20 07:00AM  
Sep-17-20 07:00AM  
Sep-03-20 08:00AM  
Aug-26-20 02:58PM  
Aug-13-20 07:00AM  
Aug-07-20 04:01PM  
Jun-26-20 08:00AM  
Jun-04-20 11:17AM  
08:00AM  
May-28-20 08:35AM  
May-21-20 08:00AM  
May-12-20 05:00PM  
May-11-20 07:00AM  
May-07-20 07:30AM  
May-04-20 08:00AM  
Apr-21-20 08:00AM  
Apr-08-20 08:00AM  
Mar-27-20 08:00AM  
Mar-09-20 04:30PM  
Mar-05-20 08:00AM  
Feb-27-20 07:25PM  
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
OYST Oyster Point Pharma, Inc. daily Stock Chart
OYST [NASD]
Oyster Point Pharma, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own0.20% Shs Outstand25.80M Perf Week4.04%
Market Cap510.16M Forward P/E- EPS next Y-3.48 Insider Trans8.07% Shs Float23.39M Perf Month-1.35%
Income-68.00M PEG- EPS next Q-0.79 Inst Own92.80% Short Float3.59% Perf Quarter-15.48%
Sales- P/S- EPS this Y-167.20% Inst Trans-0.04% Short Ratio12.02 Perf Half Y-24.76%
Book/sh8.01 P/B2.38 EPS next Y-37.50% ROA-37.70% Target Price- Perf Year-36.58%
Cash/sh8.00 P/C2.38 EPS next 5Y- ROE-39.60% 52W Range17.24 - 41.37 Perf YTD1.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.95% Beta-
Dividend %- Quick Ratio22.80 Sales past 5Y- Gross Margin- 52W Low10.50% ATR1.07
Employees30 Current Ratio22.80 Sales Q/Q- Oper. Margin- RSI (14)47.89 Volatility5.85% 5.17%
OptionableNo Debt/Eq0.00 EPS Q/Q-17.40% Profit Margin- Rel Volume2.01 Prev Close18.72
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume69.86K Price19.05
Recom2.00 SMA200.83% SMA50-7.37% SMA200-22.37% Volume137,245 Change1.76%
Nov-25-19Initiated Piper Jaffray Overweight $35
Nov-25-19Initiated JP Morgan Overweight $26
Nov-25-19Initiated Cowen Outperform $40
Jan-18-21 07:05AM  
Dec-29-20 04:01PM  
Dec-18-20 07:00AM  
Dec-12-20 11:36PM  
Dec-07-20 07:00AM  
Dec-01-20 04:01PM  
Nov-25-20 09:00AM  
Nov-13-20 07:00AM  
Nov-06-20 11:31AM  
Nov-05-20 04:01PM  
02:45PM  
Oct-29-20 04:01PM  
Oct-08-20 04:01PM  
Sep-11-20 08:00AM  
Aug-17-20 10:33AM  
Aug-11-20 01:02PM  
01:01PM  
Aug-05-20 07:00AM  
Jul-31-20 04:01PM  
Jun-01-20 11:39AM  
May-28-20 09:07AM  
May-24-20 12:25PM  
May-19-20 06:08PM  
May-15-20 02:02AM  
May-12-20 04:20PM  
May-11-20 10:31PM  
06:05AM  
06:00AM  
May-04-20 04:05PM  
Mar-30-20 07:30AM  
Feb-27-20 04:01PM  
Feb-24-20 08:00AM  
08:00AM  
Jan-12-20 08:00PM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-17-19 08:00AM  
Dec-03-19 03:29PM  
07:00AM  
Nov-25-19 08:00AM  
Nov-22-19 05:12PM  
Nov-05-19 09:10AM  
Oct-28-19 08:20AM  
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lochner DanielChief Financial OfficerSep 25Option Exercise11.514,00046,04014,300Sep 28 06:12 PM
Lochner DanielChief Financial OfficerAug 11Option Exercise11.514,00046,0404,000Aug 12 08:32 PM
Snisarenko JohnChief Commercial OfficerAug 10Buy25.974,000103,8807,000Aug 11 04:03 PM
Nau JeffreyPresident and CEOJul 28Option Exercise1.025,0005,1005,000Jul 30 07:37 PM